The blockade of persistent and excessive sterile inflammatory responses with specific antagonists of NLRP3 inflammasome could be a promising therapeutic strategy for the prevention or treatment of the adverse outcomes associated with kidney injury. The gene discussed is NLRP3; the disease is kidney injury.